MicroRNA‑103 regulates tumorigenesis in colorectal cancer by targeting ZO‑1

Ke,Jin; Shao,Weiwei; Jiang,Yasu; Xu,Junfei; Li,Feng; Qin,Jun

doi:10.3892/mmr.2017.8007

MicroRNA‑103 regulates tumorigenesis in colorectal cancer by targeting ZO‑1

Authors:
- Jin Ke
- Weiwei Shao
- Yasu Jiang
- Junfei Xu
- Feng Li
- Jun Qin
View Affiliations

Affiliations: Department of General Surgery, The Affiliated Hospital of Nantong University, Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of General Surgery, The Fourth Affiliated Hospital of Nantong University, Nantong University, Yancheng, Jiangsu 224000, P.R. China, Department of General Surgery, The Second Affiliated Hospital of Nantong University, Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of Gastroenterology, The Affiliated Hospital of Nantong University, Nantong University, Nantong, Jiangsu 226001, P.R. China
Published online on: November 7, 2017 https://doi.org/10.3892/mmr.2017.8007
Pages: 783-788
Copyright: © Ke et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Given the emerging role of microRNAs (miRs) in cancer progression, the present study investigated the role and underlying mechanism of miR‑103 in colorectal cancer (CRC). Reverse transcription‑quantitative polymerase chain reaction was conducted to quantify the expression levels of miR‑103 in clinical specimens and cell lines. The role of miR‑103 in CRC was examined using MTT, colony formation and transwell assays. In addition, a luciferase reporter assay was used to confirm an associated between the 3' untranslated region of zonula occuldens‑1 (ZO‑1) and miR‑103. The results demonstrated that miR‑103 was upregulated in CRC. Overexpression of miR‑103 promoted CRC cell proliferation and migration in vitro, whereas downregulation of miR‑103 inhibited cell proliferation and migration. ZO‑1 was identified as a direct target of miR‑103, revealing its expression to be inversely correlated with miR‑103 expression in CRC samples. In conclusion, the present study revealed that miR‑103 has strong tumor‑promoting effects via of targeting ZO‑1 in CRC and has potential development of miRNA‑based targeted approaches for the treatment of CRC.

View Figures

View References

1	Zhao P, Dai M, Chen W and Li N: Cancer trends in China. Jpn J Clin Oncol. 40:281–285. 2010. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
3	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
4	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
5	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
6	Lee YS and Dutta A: The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 21:1025–1030. 2007. View Article : Google Scholar : PubMed/NCBI
7	Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, D'Urso L, Pagliuca A, Biffoni M, Labbaye C, et al: The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 14:1271–1277. 2008. View Article : Google Scholar : PubMed/NCBI
8	Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M, et al: A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 129:1401–1414. 2007. View Article : Google Scholar : PubMed/NCBI
9	Ellis KL, Cameron VA, Troughton RW, Frampton CM, Ellmers LJ and Mark RA: Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail. 15:1138–1147. 2013. View Article : Google Scholar : PubMed/NCBI
10	Yu D, Zhou H, Xun Q, Xu X, Ling J and Hu Y: microRNA-103 regulates the growth and invasion of endometrial cancer cells through the downregulation of tissue inhibitor of metalloproteinase 3. Oncol Lett. 3:1221–1226. 2012.PubMed/NCBI
11	Annibali D, Gioia U, Savino M, Laneve P, Caffarelli E and Nasi S: A new module in neural differentiation control: Two microRNAs upregulated by retinoic acid, miR-9 and −103, target the differentiation inhibitor ID2. PLoS One. 7:e402692012. View Article : Google Scholar : PubMed/NCBI
12	Weber DG, Johnen G, Bryk O, Jöckel KH and Brüning T: Identification of miRNA-103 in the cellular fraction of human peripheral blood as a potential biomarker for malignant mesothelioma-a pilot study. PLoS One. 7:e302212012. View Article : Google Scholar : PubMed/NCBI
13	Hong Z, Feng Z, Sai Z and Tao S: PER3, a novel target of miR-103, plays a suppressive role in colorectal cancer in vitro. BMB Rep. 47:500–505. 2014. View Article : Google Scholar : PubMed/NCBI
14	Mazzoccoli G, Panza A, Valvano MR, Palumbo O, Carella M, Pazienza V, Biscaglia G, Tavano F, Di Sebastiano P, Andriulli A and Piepoli A: Clock gene expression levels and relationship with clinical and pathological features in colorectal cancer patients. Chronobiol Int. 28:841–851. 2011. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Zhang Y, Qu X, Li C, Fan Y, Che X, Wang X, Cai Y, Hu X and Liu Y: miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1. Tumour Biol. 36:2277–2285. 2015. View Article : Google Scholar : PubMed/NCBI
17	Brewster BL, Rossiello F, French JD, Edwards SL, Wong M, Wronski A, Whiley P, Waddell N, Chen X, Bove B, et al: Identification of fifteen novel germline variants in the BRCA1 3′UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site. Hum Mutat. 33:1665–1675. 2012. View Article : Google Scholar : PubMed/NCBI
18	Chen HY, Lin YM, Chung HC, Lang YD, Lin CJ, Huang J, Wang WC, Lin FM, Chen Z, Huang HD, et al: miR-103/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4. Cancer Res. 72:3631–3641. 2012. View Article : Google Scholar : PubMed/NCBI
19	Trajkovski M, Hausser J, Soutschek J, Bhat B, Akin A, Zavolan M, Heim MH and Stoffel M: MicroRNAs 103 and 107 regulate insulin sensitivity. Nature. 474:649–653. 2011. View Article : Google Scholar : PubMed/NCBI
20	Chai Z, Goodenough DA and Paul DL: Cx50 requires an intact PDZ-binding motif and ZO-1 for the formation of functional intercellular channels. Mol Biol Cell. 22:4503–4512. 2011. View Article : Google Scholar : PubMed/NCBI
21	Giri S, Poindexter KM, Sundar SN and Firestone GL: Arecoline induced disruption of expression and localization of the tight junctional protein ZO-1 is dependent on the HER 2 expression in human endometrial Ishikawa cells. BMC Cell Biol. 11:532010. View Article : Google Scholar : PubMed/NCBI
22	Kawauchiya T, Takumi R, Kudo Y, Takamori A, Sasagawa T, Takahashi K and Kikuchi H: Correlation between the destruction of tight junction by patulin treatment and increase of phosphorylation of ZO-1 in Caco-2 human colon cancer cells. Toxicol Lett. 205:196–202. 2011. View Article : Google Scholar : PubMed/NCBI
23	Van Itallie CM, Balda MS and Anderson JM: Epidermal growth factor induces tyrosine phosphorylation and reorganization of the tight junction protein ZO-1 in A431 cells. J Cell Sci. 108:1735–1742. 1995.PubMed/NCBI
24	Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB and Gardner TW: Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem. 274:23463–23467. 1999. View Article : Google Scholar : PubMed/NCBI
25	Németh Z, Szász AM, Somorácz A, Tátrai P, Németh J, Gyorffy H, Szíjártó A, Kupcsulik P, Kiss A and Schaff Z: Zonula occludens-1, occludin and E-cadherin protein expression in biliary tract cancers. Pathol Oncol Res. 15:533–539. 2009. View Article : Google Scholar : PubMed/NCBI
26	Martin TA, Watkins G, Mansel RE and Jiang WG: Loss of tight junction plaque molecules in breast cancer tissues is associated with a poor prognosis in patients with breast cancer. Eur J Cancer. 40:2717–2725. 2004. View Article : Google Scholar : PubMed/NCBI
27	Zhu H, Lu J, Wang X, Zhang H, Tang X, Zhu J and Mao Y: Upregulated ZO-1 correlates with favorable survival of gastrointestinal stromal tumor. Med Oncol. 30:6312013. View Article : Google Scholar : PubMed/NCBI
28	Orbán E, Szabó E, Lotz G, Kupcsulik P, Páska C, Schaff Z and Kiss A: Different expression of occludin and ZO-1 in primary and metastatic liver tumors. Pathol Oncol Res. 14:299–306. 2008. View Article : Google Scholar : PubMed/NCBI
29	Ni S, Xu L, Huang J, Feng J, Zhu H, Wang G and Wang X: Increased ZO-1 expression predicts valuable prognosis in non-small cell lung cancer. Int J Clin Exp Pathol. 6:2887–2895. 2013.PubMed/NCBI